Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

Joseph A. Lewnard(University of California, Berkeley), Sara Y. Tartof(Kaiser Permanente), Laura Puzniak(Pfizer (United States)), Sally F. Shaw(Kaiser Permanente), Harpreet S. Takhar(Kaiser Permanente), Vennis Hong(Kaiser Permanente), Jeniffer S. Kim(Kaiser Permanente), Deborah E. Malden(Kaiser Permanente), Luis Jódar(Pfizer (United States)), Bradley K. Ackerson, John M. McLaughlin(Pfizer (United States)), Bruno Lewin(Kaiser Permanente)
The Lancet Infectious Diseases
March 15, 2023
10.1016/s1473-3099(23)00118-4
Cited by 130

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k
A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care
|CHEST Journal|2014|219
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
|Open Forum Infectious Diseases|2022|212
Effect on Survival of Longer Intervals Between Confirmed Diagnosis and Treatment Initiation Among Low-Income Women With Breast Cancer
|Journal of Clinical Oncology|2012|211